Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biosearch Technologies Acquires European Companies VitraBio and DNA Technology

By LabMedica International staff writers
Posted on 26 Feb 2013
Biosearch Technologies, Inc. More...
(Novato, CA, USA), a leading supplier of customized oligonucleotides, specialty amidites, and CPGs (controlled-pore glass) to the research and diagnostics markets, has acquired the oligonucleotide manufacturing division of the company DNA Technology, A/S (Aarhus, Denmark) and CPG manufacturer VitraBio, GmbH (Steinach, Germany).

Biosearch, with the acquisition of DNA Technology, has added a highly accomplished production team with a quality system and an established European customer base concentrated in the Nordic countries. DNA Technology is focused on the production of modified oligos, and will take advantage of the full access to the range of specialty modifications generated by Biosearch. Furthermore, Biosearch will provide cutting edge manufacturing applications and access to its large intellectual property (IP) range, enabling DNA Technology to expand production capabilities and product range to better serve a growing customer base.

With the acquisition of German controlled-pore glass (CPG) manufacturer VitraBio in September 2011, Biosearch gains control over VitraBio’s sophisticated CPG manufacturing technology and innovative production facility, which expands its already extensive range of oligo synthesis tools and processes. Biosearch plans to bring chemical manufacturing capabilities to VitraBio’s Steinach facility to enhance existing US production of specialty amidites and modified CPGs, in addition to continuing production of DNA/RNA synthesis supports for the research and therapeutic oligo markets.

The acquisition of DNA Technology and VitraBio denotes Biosearch’s increasing focus on supporting European biotechnology and diagnostic markets. Furthermore, Biosearch has secured significant manufacturing redundancy for its North American operations as well as a strong base from which to expand sales, production, and regulated contract-manufacturing capabilities throughout Europe.

Established in 1992, DNA Technology is a provider of custom-made synthetic oligonucleotides in the Nordic countries. A key focus of the company is the production of highly modified synthetic DNA and RNA to serve life science research and healthcare markets. The company is currently ISO 9001:2008 certified, and first certified to the ISO 9002 standard in 1997. DNA Technology moved in 2007 to a newly renovated facility in Risskov, a suburban district of the city of Aarhus.

Founded in 2003, VitraBio is an ISO 9001:2008-certified company and it is one of the few who possess the expertise and IP range to manufacture highly specialized controlled-pore glass (CPG) typically utilized as a support in solid-phase oligonucleotide synthesis. The manufacturing plant is suited for large-scale manufacturing of CPGs and phosphoramidites and provides ample space for continued expansion of production activities.

Biosearch Technologies is an ISO 9001:2008-certified company founded in 1993, Biosearch is focused on the design, development, and manufacture of advanced oligonucleotide-based tools. Products include fluorophores (CAL Fluor, Quasar, and Pulsar dyes) and dark quenchers (Black Hole Quencher dyes) to be included in custom-synthesized probe formats for real-time, quantitative PCR, Stellaris RNA fluorescence in situ hybridization (FISH), and other genomic-based applications. Biosearch’s markets include pharmaceutical, in vitro diagnostic, biotechnology, ag/bio, environmental and food testing, public health, and biodefense sectors.

Related Links:

Biosearch Technologies
DNA Technology
VitraBio




New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.